35
Participants
Start Date
December 8, 2023
Primary Completion Date
July 30, 2027
Study Completion Date
November 30, 2027
Latozinemab
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
UZ Leuven, Leuven
Irving Institute for Clinical and Translational Research, New York
University of Pennsylvania, Philadelphia
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35, Milan
IRCCS - Centro S. Giovanni di Dio Fatebenefratelli, Brescia
Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena
University of Cincinnati Gardner Neuroscience Institute, Cincinnati
Mayo Comprehensive Cancer Center - PPDS, Rochester
Groupe Hospitalier Pitié Salpétrière, Paris
Dignity Health - Arizona, Phoenix
Universitätsklinikum Ulm - Leimgrubenweg 12-14, Ulm
Parkwood Institute, London
Sunnybrook Health Sciences Centre, Toronto
Erasmus MC-Dr. Molewaterplein 40, Rotterdam
Centro Hospitalar E Universitario de Coimbra EPE, Coimbra
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria, Lisbon
Karolinska Universitetssjukhuset Huddinge, Huddinge
University College London, London
Lead Sponsor
Alector Inc.
INDUSTRY